Olaratumab Approved for Soft-Tissue Sarcoma.
The FDA has granted accelerated approval to the monoclonal antibody olaratumab, combined with doxorubicin, as first-line therapy for patients with inoperable soft-tissue sarcoma. In a randomized phase II trial, the median overall survival was 26.5 months for patients who received this combination, versus 14.7 months for those who received only doxorubicin.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use*; D017277:Drug Approval; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy*; D008297:Male; D012509:Sarcoma / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D004317:Doxorubicin; C000589393:olaratumab